




RealRate

PHARMACEUTICAL 2020

Xenon Pharmaceuticals Inc
Rank 150 of 363



XENON



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Xenon Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenon Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Xenon Pharmaceuticals Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 272%, being 34% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	144,866
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	43,379
Liabilities, Non-Current	12,341
Other Assets	1,171
Other Compr. Net Income	0
Other Expenses	1,411
Other Liabilities	0
Other Net Income	2,635
Other Revenues	6,829
Property and Equipment	1,660
Research and Development	38,845
Selling, General and Administrative Expense	10,803

Output Variable	Value in 1000 USD
Assets	147,697
Liabilities	55,720
Expenses	51,059
Revenues	6,829
Stockholders Equity	91,977
Net Income	-41,595
Comprehensive Net Income	-41,595
BaseVar	131,970
ECR before LimitedLiability	156%
Economic Capital Ratio	272%